MCID: DCT002
MIFTS: 51

Ductal Carcinoma in Situ malady

Categories: Cancer diseases

Aliases & Classifications for Ductal Carcinoma in Situ

Aliases & Descriptions for Ductal Carcinoma in Situ:

Name: Ductal Carcinoma in Situ 12 29 14
Noninfiltrating Intraductal Carcinoma 69

Classifications:



External Ids:

Disease Ontology 12 DOID:0060074

Summaries for Ductal Carcinoma in Situ

MalaCards based summary : Ductal Carcinoma in Situ, also known as noninfiltrating intraductal carcinoma, is related to hidradenoma and comedo carcinoma. An important gene associated with Ductal Carcinoma in Situ is AKT1 (AKT Serine/Threonine Kinase 1), and among its related pathways/superpathways are ERK Signaling and GPCR Pathway. The drugs Nolvadex and Tamoxifen have been mentioned in the context of this disorder. Affiliated tissues include breast, lymph node and testes, and related phenotypes are Decreased viability and cellular

Wikipedia : 71 Ductal carcinoma in situ (DCIS), also known as intraductal carcinoma, is a pre-cancerous or non-invasive... more...

Related Diseases for Ductal Carcinoma in Situ

Diseases related to Ductal Carcinoma in Situ via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 273)
id Related Disease Score Top Affiliating Genes
1 hidradenoma 29.6 BRCA1 BRCA2 CCND1 CDKN2A TP53
2 comedo carcinoma 11.0
3 breast cancer 10.7
4 breast ductal carcinoma 10.5
5 mouth disease 10.4 ERBB2 PGR
6 bartholin's gland benign neoplasm 10.4 ESR1 PGR
7 pineal region mature teratoma 10.4 EGFR ERBB2
8 aortitis 10.4 PGR TP53
9 glioma 10.4 ERBB2 ESR1 PGR
10 cardiovascular organ benign neoplasm 10.3 ESR1 PGR
11 appendix leiomyoma 10.3 ESR1 PGR
12 bronchus adenoma 10.3 ESR1 PGR
13 rectal neoplasm 10.3 ERBB2 ESR1 PGR
14 bladder clear cell adenocarcinoma 10.3 ESR1 TP53
15 triple-receptor negative breast cancer 10.3 EGFR ERBB2 PGR
16 skin sarcoma 10.3 EGFR ERBB2 PGR
17 vaginal adenosarcoma 10.3 ESR1 PGR TP53
18 aorto-ventricular tunnel 10.3 BRCA1 BRCA2
19 her2-receptor positive breast cancer 10.3 ERBB2 ESR1 PGR
20 wolffian adnexal neoplasm 10.3 EGFR TP53
21 adult central nervous system mature teratoma 10.3 CCND1 ERBB2 TP53
22 linitis plastica 10.3 CDH1 TP53
23 gallbladder papillomatosis 10.3 AKT1 PGR TP53
24 kunjin encephalitis 10.3 BRCA1 BRCA2 ERBB2
25 pediatric intraocular retinoblastoma 10.3 ESR1 KRT14 PGR
26 autoimmune disease of cardiovascular system 10.3 BRCA1 BRCA2 PGR
27 heart malignant hemangiopericytoma 10.3 BRCA1 BRCA2 PGR
28 ovarian benign neoplasm 10.3 ESR1 PGR
29 ovarian clear cell malignant adenofibroma 10.3 ESR1 KRT14 PGR
30 arthus reaction 10.3 ERBB2 ESR1 PGR TP53
31 clear cell adenofibroma 10.3 CDKN2A TP53
32 osteogenesis imperfecta 10.3 CYP19A1 ESR1 PGR
33 acute thyroiditis 10.3 CYP19A1 ESR1 PGR
34 perinatal jaundice due to hepatocellular damage 10.3 CYP19A1 ESR1 PGR
35 pericardium leiomyoma 10.3 CDKN2A PGR TP53
36 renal infectious disease 10.3 ERBB2 KRT8
37 necrobiosis lipoidica 10.3 ERBB2 ESR1 PGR TP53
38 mediastinum synovial sarcoma 10.3 BRCA1 BRCA2 TP53
39 deafness, autosomal recessive 74 10.3 CYP19A1 ESR1 PGR
40 lacrimal gland adenoid cystic carcinoma 10.3 CDKN2A TP53
41 pneumonia 10.3 BRCA1 BRCA2 PGR
42 vulva basal cell carcinoma 10.3 CDKN2A ESR1 PGR
43 plexiform neurofibroma 10.3 ESR1 PGR
44 histiocytic and dendritic cell cancer 10.2 BRCA1 ERBB2 ESR1 PGR
45 esophagus sarcoma 10.2 CYP19A1 ESR1 PGR
46 multicentric papillary thyroid carcinoma 10.2 EGFR KRT14 TP53
47 plague 10.2 EGFR ERBB2 ESR1 TP53
48 skeletal tuberculosis 10.2 CCND1 CDKN2A ERBB2
49 organ system benign neoplasm 10.2 BRCA1 ERBB2 ESR1 PGR
50 endometrial squamous cell carcinoma 10.2 AKT1 CDKN2A TP53

Graphical network of the top 20 diseases related to Ductal Carcinoma in Situ:



Diseases related to Ductal Carcinoma in Situ

Symptoms & Phenotypes for Ductal Carcinoma in Situ

GenomeRNAi Phenotypes related to Ductal Carcinoma in Situ according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 9.83 EGFR
2 Decreased viability GR00221-A-1 9.83 AKT1 CDKN2A EGFR ESR1
3 Decreased viability GR00221-A-2 9.83 AKT1 ESR1
4 Decreased viability GR00221-A-3 9.83 AKT1 CDKN2A ERBB2
5 Decreased viability GR00221-A-4 9.83 AKT1 CDKN2A EGFR ERBB2 ESR1
6 Increased cell death HMECs cells GR00103-A-0 9.1 BRCA1 EGFR PGR PIP S100A7 TP53

MGI Mouse Phenotypes related to Ductal Carcinoma in Situ:

44 (show all 25)
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.48 TP53 AKT1 BRCA1 BRCA2 CCND1 CDH1
2 growth/size/body region MP:0005378 10.48 KRT8 PTGS2 TP53 AKT1 BRCA1 BRCA2
3 digestive/alimentary MP:0005381 10.47 BRCA1 BRCA2 CCND1 CDH1 CDKN2A CYP19A1
4 cardiovascular system MP:0005385 10.46 AKT1 BRCA1 CCND1 CDH1 CDKN2A CYP19A1
5 endocrine/exocrine gland MP:0005379 10.46 AKT1 BRCA1 BRCA2 CCND1 CDH1 CDKN2A
6 homeostasis/metabolism MP:0005376 10.46 AKT1 BRCA1 BRCA2 CCND1 CDH1 CDKN2A
7 hematopoietic system MP:0005397 10.44 AKT1 BRCA1 BRCA2 CCND1 CDKN2A CLDN7
8 integument MP:0010771 10.44 ESR1 KRT14 KRT5 PGR PTGS2 TP53
9 immune system MP:0005387 10.42 ESR1 KRT14 KRT8 PGR PIP PTGS2
10 behavior/neurological MP:0005386 10.4 AKT1 BRCA1 BRCA2 CCND1 CDKN2A CYP19A1
11 mortality/aging MP:0010768 10.4 AKT1 BRCA1 BRCA2 CCND1 CDH1 CDKN2A
12 embryo MP:0005380 10.37 AKT1 BRCA1 BRCA2 CDH1 CDKN2A EGFR
13 neoplasm MP:0002006 10.27 EGFR ERBB2 ESR1 AKT1 BRCA1 BRCA2
14 adipose tissue MP:0005375 10.22 AKT1 BRCA1 CYP19A1 EGFR ESR1 KRT14
15 muscle MP:0005369 10.18 AKT1 BRCA1 CDKN2A CYP19A1 EGFR ERBB2
16 nervous system MP:0003631 10.17 AKT1 BRCA1 BRCA2 CCND1 CDKN2A CYP19A1
17 normal MP:0002873 10.15 AKT1 BRCA1 BRCA2 CCND1 CDH1 CYP19A1
18 limbs/digits/tail MP:0005371 10.13 BRCA2 EGFR ERBB2 ESR1 KRT5 PGR
19 liver/biliary system MP:0005370 10.11 ESR1 KRT8 PTGS2 TP53 AKT1 CDKN2A
20 reproductive system MP:0005389 10.06 AKT1 BRCA1 BRCA2 CCND1 CDH1 CDKN2A
21 no phenotypic analysis MP:0003012 10.01 CDH1 CDKN2A EGFR ESR1 KRT5 PGR
22 pigmentation MP:0001186 9.8 BRCA1 CDKN2A CYP19A1 EGFR KRT14 TP53
23 renal/urinary system MP:0005367 9.8 PTGS2 TP53 BRCA1 CLDN7 CYP19A1 EGFR
24 respiratory system MP:0005388 9.65 ESR1 KRT14 PTGS2 TP53 BRCA1 CCND1
25 skeleton MP:0005390 9.4 BRCA1 BRCA2 CCND1 CDKN2A CYP19A1 EGFR

Drugs & Therapeutics for Ductal Carcinoma in Situ

FDA approved drugs:

id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Nolvadex 17 46 TAMOXIFEN CITRATE AstraZeneca Approved October 1998

Drugs for Ductal Carcinoma in Situ (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 201)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tamoxifen Approved Phase 3,Phase 2,Phase 1 10540-29-1 2733526
2
Cyclophosphamide Approved, Investigational Phase 3,Phase 2 50-18-0, 6055-19-2 2907
3
Epirubicin Approved Phase 3,Phase 2 56420-45-2 41867
4
Carboplatin Approved Phase 3,Phase 2 41575-94-4 10339178 498142 38904
5
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
6
Trastuzumab Approved, Investigational Phase 3,Phase 2,Phase 1 180288-69-1 9903
7
Anastrozole Approved, Investigational Phase 3,Phase 2 120511-73-1 2187
8
Medroxyprogesterone acetate Approved, Investigational Phase 3 71-58-9
9
Fluorouracil Approved Phase 3 51-21-8 3385
10
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
11
Letrozole Approved, Investigational Phase 3,Phase 2,Phase 1 112809-51-5 3902
12
Progesterone Approved, Vet_approved Phase 3,Phase 2,Early Phase 1 57-83-0 5994
13
Pertuzumab Approved Phase 3,Phase 2,Phase 1 145040-37-5, 380610-27-5 2540
14
Oxybutynin Approved, Investigational Phase 3 5633-20-5 4634
15
Metformin Approved Phase 3 657-24-9 14219 4091
16
Exemestane Approved, Investigational Phase 3 107868-30-4 60198
17
Paclitaxel Approved, Vet_approved Phase 3,Phase 2 33069-62-4 36314
18
Pembrolizumab Approved Phase 3,Early Phase 1 1374853-91-4
19
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
20
leucovorin Approved, Nutraceutical Phase 3 58-05-9 54575, 6560146 143
21
Docetaxel Approved May 1996, Investigational Phase 3,Phase 2 114977-28-5 148124 9877265
22
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
23 Antineoplastic Agents, Hormonal Phase 3,Phase 2,Phase 1
24 Bone Density Conservation Agents Phase 3,Phase 2,Phase 1
25 Estrogen Antagonists Phase 3,Phase 2,Phase 1
26 Estrogen Receptor Modulators Phase 3,Phase 2,Phase 1
27 Estrogens Phase 3,Phase 2,Phase 1
28 Hormone Antagonists Phase 3,Phase 2,Phase 1,Early Phase 1
29 Hormones Phase 3,Phase 2,Phase 1,Early Phase 1
30 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1,Early Phase 1
31 Selective Estrogen Receptor Modulators Phase 3,Phase 2,Phase 1
32 Alkylating Agents Phase 3,Phase 2
33 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
34 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
35 Antimetabolites Phase 3,Phase 2,Phase 1
36 Antimetabolites, Antineoplastic Phase 3,Phase 2
37 Antimitotic Agents Phase 3,Phase 2
38 Antineoplastic Agents, Alkylating Phase 3,Phase 2
39 Antirheumatic Agents Phase 3,Phase 2,Phase 1
40 Immunosuppressive Agents Phase 3,Phase 2
41 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
42 Antineoplastic Agents, Phytogenic Phase 3,Phase 2
43 Aromatase Inhibitors Phase 3,Phase 2,Phase 1
44 Steroid Synthesis Inhibitors Phase 3,Phase 2,Phase 1
45 Anti-Allergic Agents Phase 3
46 Anti-Inflammatory Agents Phase 3,Phase 1,Phase 2
47 Dermatologic Agents Phase 3
48 mometasone furoate Phase 3 83919-23-7
49 Contraceptive Agents Phase 3,Early Phase 1
50 Contraceptive Agents, Male Phase 3

Interventional clinical trials:

(show top 50) (show all 213)
id Name Status NCT ID Phase
1 Phase IV Trial to Evaluate Breast Brachytherapy Using the Mammosite-Ml® Completed NCT01448447 Phase 4
2 Electronic Xoft Intersociety Brachytherapy Trial: Electronic Brachytherapy (EBT) For Treatment of Early Stage Breast Cancer Completed NCT00742222 Phase 4
3 Breast-Conserving Surgery and Whole-Breast Radiation Therapy With or Without Additional Radiation Therapy to the Tumor in Treating Women With Ductal Carcinoma in Situ Unknown status NCT00907868 Phase 3
4 Evaluation of the Diagnostic Performance of MRI±Biopsy to Optimize Resection of Ductal Carcinoma In Situ (DCIS) Breast Cancer Completed NCT01112254 Phase 3
5 Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy Completed NCT00053898 Phase 3
6 Genetic Counseling or Usual Care in Helping Women With Newly Diagnosed Ductal Carcinoma In Situ or Stage I, Stage II, or Stage IIIA Breast Cancer Make Treatment Decisions Completed NCT00262899 Phase 3
7 Mometasone Furoate in Preventing Radiation Dermatitis in Patients Undergoing Radiation Therapy to the Breast or Chest Wall for Invasive Breast Cancer or Ductal Carcinoma in Situ Completed NCT00438659 Phase 3
8 Intraoperative Gamma Camera for Breast Cancer Surgery Completed NCT00757302 Phase 3
9 Hormone Replacement Therapy for Hot Flashes and/or Vaginal Symptoms in Postmenopausal Women Receiving Tamoxifen for Breast Cancer Completed NCT00026286 Phase 3
10 S9630, Medroxyprogesterone in Treating Women With Breast Cancer Completed NCT00002920 Phase 3
11 Study of Docetaxel in Breast Cancer Patients Completed NCT00174707 Phase 3
12 Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women Completed NCT00003906 Phase 3
13 Oxybutynin Chloride in Managing Hot Flashes Recruiting NCT02961790 Phase 3
14 Metformin Hydrochloride in Patients With Atypical Hyperplasia or In Situ Breast Cancer to Placebo in Decreasing Atypical Cells in Patients With Atypical Hyperplasia or in Situ Breast Cancer Recruiting NCT01905046 Phase 3
15 Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Recruiting NCT01272037 Phase 3
16 Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522) Recruiting NCT03036488 Phase 3
17 Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Active, not recruiting NCT00769379 Phase 3
18 Radiation Doses and Fractionation Schedules in Non-low Risk Ductal Carcinoma In Situ (DCIS) of the Breast Active, not recruiting NCT00470236 Phase 3
19 Adjuvant Tamoxifen Compared With Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ Active, not recruiting NCT00072462 Phase 3
20 Radiation Therapy With or Without Optional Tamoxifen in Treating Women With Ductal Carcinoma in Situ Active, not recruiting NCT00003857 Phase 3
21 APBI Versus EBRT Therapy After Breast Conserving Surgery for Low-risk Breast Cancer Active, not recruiting NCT00402519 Phase 3
22 RAPID: Randomized Trial of Accelerated Partial Breast Irradiation Active, not recruiting NCT00282035 Phase 3
23 Spect Analysis of Cardiac Perfusion Changes After Whole Breast/Chest Wall Radiation Therapy With Active Breathing Coordinator Active, not recruiting NCT00321048 Phase 3
24 Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery Active, not recruiting NCT01349322 Phase 3
25 Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer Active, not recruiting NCT00878709 Phase 3
26 A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE) Active, not recruiting NCT01772472 Phase 3
27 A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer Active, not recruiting NCT01358877 Phase 3
28 Trial of Low Dose Tamoxifen in Women With Breast Intraepithelial Neoplasia Active, not recruiting NCT01357772 Phase 3
29 Letrozole or Tamoxifen in Treating Postmenopausal Women With Breast Cancer Active, not recruiting NCT00004205 Phase 3
30 Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer Active, not recruiting NCT00083174 Phase 3
31 Management of Low-risk DCIS Not yet recruiting NCT02492607 Phase 3
32 Risedronate in Improving Bone Mineral Density and Bone Health in Postmenopausal Women With Ductal Carcinoma In Situ Enrolled in Clinical Trial CRUK-IBIS-II-DCIS Withdrawn NCT00324714 Phase 3
33 Study Of Intraductal Carboplatin In Women With Ductal Carcinoma In Situ (DCIS) Unknown status NCT00669747 Phase 2
34 Effect of Omega 3 on Atrophic Vaginitis in Breast Cancer Survivors Unknown status NCT02150525 Phase 2
35 Dose Optimization for Pulsed-dose-rate (PDR)/High-dose-rate (HDR) Brachytherapy Alone for Early Breast Cancer Unknown status NCT01175694 Phase 2
36 Cisplatin-monotherapy in the Treatment of BRCA1 Positive Breast Cancer Patients in Poland Unknown status NCT01630226 Phase 2
37 "Phase II Study of PET Guided Neoadjuvant Chemotherapy (NAC) and Oncotype Guided Hormonal Therapy of Breast Cancer" Unknown status NCT01641406 Phase 2
38 4-Hydroxytamoxifen or Tamoxifen Citrate in Treating Women With Newly Diagnosed Ductal Breast Carcinoma in Situ Completed NCT00952731 Phase 2
39 Study of the Efficacy of Chloroquine in the Treatment of Ductal Carcinoma in Situ (The PINC Trial) Completed NCT01023477 Phase 1, Phase 2
40 Effect of Fluvastatin on Biomarkers in Women Who Are Undergoing Surgery for Ductal Carcinoma In Situ or Stage I Breast Cancer Completed NCT00416403 Phase 2
41 Radiation Therapy After Lumpectomy in Treating Women With Ductal Carcinoma in Situ or Invasive Breast Cancer Completed NCT00054301 Phase 2
42 MammoSite as Sole Radiation Therapy Technique for Ductal Carcinoma In-Situ Completed NCT00586326 Phase 2
43 Ten Years Results of a Score System to Address Adjuvant Therapies After Breast Conserving Surgery for Ductal Carcinoma in Situ of the Breast Completed NCT03002766 Phase 2
44 Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor Completed NCT01372618 Phase 2
45 Broccoli Sprout Extract in Treating Women Who Have Had a Mammogram and Breast Biopsy Completed NCT00843167 Phase 2
46 Simvastatin and Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ or Invasive Breast Cancer Completed NCT00354640 Phase 2
47 DC Vaccine for Patients With Ductal Carcinoma In Situ Completed NCT02061332 Phase 1, Phase 2
48 Simvastatin in Preventing a New Breast Cancer in Women at High Risk for a New Breast Cancer Completed NCT00334542 Phase 2
49 Anastrozole in Treating Postmenopausal Women With DCIS or Stage I-III Breast Cancer Completed NCT00244959 Phase 2
50 Zoledronic Acid in Aromatase Inhibitor Induced Musculoskeletal Symptoms Completed NCT01194440 Phase 2

Search NIH Clinical Center for Ductal Carcinoma in Situ

Genetic Tests for Ductal Carcinoma in Situ

Genetic tests related to Ductal Carcinoma in Situ:

id Genetic test Affiliating Genes
1 Ductal Carcinoma in Situ 29

Anatomical Context for Ductal Carcinoma in Situ

MalaCards organs/tissues related to Ductal Carcinoma in Situ:

39
Breast, Lymph Node, Testes, Monocytes, B Cells, Cervix, Salivary Gland

Publications for Ductal Carcinoma in Situ

Articles related to Ductal Carcinoma in Situ:

(show top 50) (show all 824)
id Title Authors Year
1
Health-related behaviors and mortality outcomes in women diagnosed with ductal carcinoma in situ. ( 28058695 )
2017
2
Identifying progression predictors of breast ductal carcinoma in situ. ( 27864452 )
2017
3
Patient-reported outcomes in ductal carcinoma in situ: A systematic review. ( 27987454 )
2017
4
Ductal Carcinoma in situ Detected during Prospective MR Imaging Screening of a Woman with a BRCA2 Mutation: The First Case Report in Japan. ( 28090007 )
2017
5
Trends in the use of implantable accelerated partial breast irradiation for ductal carcinoma in situ: Implications of the recent amendments to the American Society for Radiation Oncology consensus guidelines. ( 28063816 )
2017
6
Recurrence outcomes after omission of postoperative radiotherapy following breast-conserving surgery for ductal carcinoma in situ of the breast: a multicenter, retrospective study in Korea (KROG 16-02). ( 28083820 )
2017
7
Factors influencing local control in patients undergoing breast conservation surgery for ductal carcinoma in situ. ( 27871025 )
2017
8
Erratum to: Subsequent risk of ipsilateral and contralateral invasive breast cancer after treatment for ductal carcinoma in situ: incidence and the effect of radiotherapy in a population-based cohort of 10,090 women. ( 27878644 )
2017
9
Trends in cardiac mortality in women with ductal carcinoma in situ. ( 27858317 )
2017
10
Genome evolution in ductal carcinoma in situ: invasion of the clones. ( 27861897 )
2017
11
The Impact of Her2 Neoadjuvant Monoclonal Antibody (Trastuzumab) Therapy in Ductal Carcinoma In Situ of the Breast. ( 27943389 )
2016
12
Thirty percent of ductal carcinoma in situ of the breast in Japan is extremely low-grade ER(+)/HER2(-) type without comedo necrosis. ( 27644557 )
2016
13
Low-Grade Malignant Proliferating Tricholemmal Tumor Associated With Occult Ductal Carcinoma In Situ of the Breast. ( 27149331 )
2016
14
Predictors of Antiestrogen Recommendation in Women With Estrogen Receptor-Positive Ductal Carcinoma In Situ. ( 27587621 )
2016
15
Contemporary management of ductal carcinoma in situ and lobular carcinoma in situ. ( 27197512 )
2016
16
Gynecomastia With Atypical Ductal Hyperplasia and Ductal Carcinoma In Situ Associated With Invasive Breast Carcinoma in a Male Patient on Antiretroviral Therapy: A Case Report. ( 26612847 )
2016
17
Sensitivity of breast MRI for ductal carcinoma in situ appearing as microcalcifications only on mammography. ( 27618803 )
2016
18
Possible Prognostic Role of HER2/Neu in Ductal Carcinoma In Situ and Atypical Ductal Proliferative Lesions of the Breast. ( 27644608 )
2016
19
Predictive factors for positive surgical margins in the treatment of breast ductal carcinoma in situ. ( 27461687 )
2016
20
No impact of breast magnetic resonance imaging on 15-year outcomes in patients with ductal carcinoma in situ or early-stage invasive breast cancer managed with breast conservation therapy. ( 27984658 )
2016
21
The distribution of ductal carcinoma in situ (DCIS) grade in 4232 women and its impact on overdiagnosis in breast cancer screening. ( 27160733 )
2016
22
Genetic predisposition to ductal carcinoma in situ of the breast. ( 26884359 )
2016
23
Her2 and Ki67 Biomarkers Predict Recurrence of Ductal Carcinoma in Situ. ( 26317313 )
2016
24
Biologic behavior and long-term outcomes of breast ductal carcinoma in situ with microinvasion. ( 27577080 )
2016
25
Confocal fluorescence microscopy to evaluate changes in adipocytes in the tumor micro-environment associated with invasive ductal carcinoma and ductal carcinoma in situ. ( 27116366 )
2016
26
Glucose Uptake and Intracellular pH in a Mouse Model of Ductal Carcinoma In situ (DCIS) Suggests Metabolic Heterogeneity. ( 27630987 )
2016
27
The Efficacy of Intraoperative Frozen Section Analysis During Breast-Conserving Surgery for Patients with Ductal Carcinoma In Situ. ( 27980416 )
2016
28
Surgical excision without whole breast irradiation for complete resection of ductal carcinoma in situ identified using strict, unified criteria. ( 27964923 )
2016
29
Tumor characteristics of ductal carcinoma in situ of breast visualized on [F-18] fluorodeoxyglucose-positron emission tomography/computed tomography: Results from a retrospective study. ( 27648168 )
2016
30
Effective treatment of ductal carcinoma in situ with a HER-2- targeted alpha-particle emitting radionuclide in a preclinical model of human breast cancer. ( 27119227 )
2016
31
Subsequent risk of ipsilateral and contralateral invasive breast cancer after treatment for ductal carcinoma in situ: incidence and the effect of radiotherapy in a population-based cohort of 10,090 women. ( 27624164 )
2016
32
Different Biological Action of Oleic Acid in ALDHhigh and ALDHlow Subpopulations Separated from Ductal Carcinoma In Situ of Breast Cancer. ( 27589390 )
2016
33
Incidental unilateral and bilateral ductal carcinoma in situ encountered in the surgical management of young male gynecomastia. ( 27612041 )
2016
34
Radiopathological features predictive of involved margins in ductal carcinoma in situ. ( 27659365 )
2016
35
Ductal Carcinoma In Situ: How Much Treatment Is Enough, How Much Is Too Much? ( 27072387 )
2016
36
Breast Ductal Carcinoma In Situ: A Literature Review of Adjuvant Hormonal Therapy. ( 28058096 )
2016
37
The immune microenvironment of breast ductal carcinoma in situ. ( 26769139 )
2016
38
PO-21 - Stromal fibroblasts in preinvasive breast cancer (ductal carcinoma in situ, DCIS) demonstrate a cancer-like procoagulant phenotypic switch that may facilitate invasion. ( 27161710 )
2016
39
Ductal carcinoma in situ diagnosed by breast needle biopsy: Predictors of invasion in the excision specimen. ( 27212695 )
2016
40
Evaluation of BRCAPRO Risk Assessment Model in Patients with Ductal Carcinoma In situ Who Underwent Clinical BRCA Genetic Testing. ( 27200080 )
2016
41
Cost Effectiveness of the Oncotype DX DCIS Score for Guiding Treatment of Patients With Ductal Carcinoma In Situ. ( 27621393 )
2016
42
Ductal Carcinoma In Situ: To Irradiate or Not to Irradiate? ( 27072388 )
2016
43
Hypofractionation Is an Acceptable Alternative to Conventional Fractionation in the Treatment of Postlumpectomy Ductal Carcinoma In Situ With Radiotherapy. ( 27889437 )
2016
44
Impact of Age on Risk of Recurrence of Ductal Carcinoma In Situ: Outcomes of 2996 Women Treated with Breast-Conserving Surgery Over 30 Years. ( 27198513 )
2016
45
Risk prediction for local versus regional/metastatic tumors after initial ductal carcinoma in situ diagnosis treated by lumpectomy. ( 27146587 )
2016
46
Prediction of invasive breast cancer using shear-wave elastography in patients with biopsy-confirmed ductal carcinoma in situ. ( 27085697 )
2016
47
Sentinel lymph node biopsy in clinically detected ductal carcinoma in situ. ( 27081649 )
2016
48
Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Ductal Carcinoma in Situ. ( 27538810 )
2016
49
Ductal Carcinoma In Situ of the Breast: Should Breast Irradiation Be Routinely Added to Surgical Excision? ( 27072386 )
2016
50
Youngest case of ductal carcinoma in situ arising within a benign phyllodes tumour: A case report. ( 27186962 )
2016

Variations for Ductal Carcinoma in Situ

Cosmic variations for Ductal Carcinoma in Situ:

9 (show all 30)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM11089 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.584T>C p.I195T 7
2 COSM44415 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.711G>C p.M237I 7
3 COSM43814 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.587G>C p.R196P 7
4 COSM10656 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.742C>T p.R248W 7
5 COSM43714 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.836G>A p.G279E 7
6 COSM44737 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.860A>G p.E287G 7
7 COSM10867 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.797G>A p.G266E 7
8 COSM6932 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.733G>A p.G245S 7
9 COSM10662 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.743G>A p.R248Q 7
10 COSM10660 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.818G>A p.R273H 7
11 COSM43559 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.517G>T p.V173L 7
12 COSM44901 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.532C>G p.H178D 7
13 COSM10701 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.824G>T p.C275F 7
14 COSM10779 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.818G>T p.R273L 7
15 COSM775 PIK3CA breast,NS,carcinoma in situ,ductal carcinoma in situ c.3140A>G p.H1047R 7
16 COSM12458 PIK3CA breast,NS,carcinoma in situ,ductal carcinoma in situ c.1634A>C p.E545A 7
17 COSM776 PIK3CA breast,NS,carcinoma in situ,ductal carcinoma in situ c.3140A>T p.H1047L 7
18 COSM760 PIK3CA breast,NS,carcinoma in situ,ductal carcinoma in situ c.1624G>A p.E542K 7
19 COSM774 PIK3CA breast,NS,carcinoma in situ,ductal carcinoma in situ c.3139C>T p.H1047Y 7
20 COSM763 PIK3CA breast,NS,carcinoma in situ,ductal carcinoma in situ c.1633G>A p.E545K 7
21 COSM754 PIK3CA breast,NS,carcinoma in situ,ductal carcinoma in situ c.1035T>A p.N345K 7
22 COSM565 NRAS breast,NS,carcinoma in situ,ductal carcinoma in situ c.35G>C p.G12A 7
23 COSM580 NRAS breast,NS,carcinoma in situ,ductal carcinoma in situ c.181C>A p.Q61K 7
24 COSM532 KRAS breast,NS,carcinoma in situ,ductal carcinoma in situ c.38G>A p.G13D 7
25 COSM521 KRAS breast,NS,carcinoma in situ,ductal carcinoma in situ c.35G>A p.G12D 7
26 COSM520 KRAS breast,NS,carcinoma in situ,ductal carcinoma in situ c.35G>T p.G12V 7
27 COSM516 KRAS breast,NS,carcinoma in situ,ductal carcinoma in situ c.34G>T p.G12C 7
28 COSM14060 ERBB2 breast,NS,carcinoma in situ,ductal carcinoma in situ c.2264T>C p.L755S 7
29 COSM19786 CDH1 breast,NS,carcinoma in situ,ductal carcinoma in situ c.779C>T p.P260L 7
30 COSM33765 AKT1 breast,NS,carcinoma in situ,ductal carcinoma in situ c.49G>A p.E17K 7

Expression for Ductal Carcinoma in Situ

Search GEO for disease gene expression data for Ductal Carcinoma in Situ.

Pathways for Ductal Carcinoma in Situ

Pathways related to Ductal Carcinoma in Situ according to GeneCards Suite gene sharing:

(show top 50) (show all 65)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.89 AKT1 BRCA1 CCND1 CDH1 CDKN2A EGFR
2
Show member pathways
13.78 AKT1 BRCA1 BRCA2 CCND1 CDKN2A EGFR
3
Show member pathways
12.84 AKT1 CDH1 ERBB2 ESR1 PTGS2 TP53
4
Show member pathways
12.72 BRCA1 BRCA2 CCND1 ESR1 TP53
5 12.64 AKT1 BRCA1 CCND1 EGFR TP53
6 12.55 BRCA1 BRCA2 CCND1 CDKN2A TP53
7
Show member pathways
12.55 AKT1 BRCA1 BRCA2 CCND1 CDH1 CDKN2A
8
Show member pathways
12.52 AKT1 CCND1 CDH1 EGFR ERBB2 MUC1
9 12.48 AKT1 CCND1 CDH1 PTGS2 TP53
10 12.42 BRCA1 CCND1 CDKN2A EGFR ERBB2 PTGS2
11 12.41 AKT1 BRCA2 CCND1 CDH1 CDKN2A EGFR
12
Show member pathways
12.4 BRCA1 CCND1 CDKN2A TP53
13 12.39 CCND1 CDH1 CDKN2A TP53
14
Show member pathways
12.38 AKT1 CCND1 CDH1 EGFR ERBB2 TP53
15
Show member pathways
12.35 AKT1 CCND1 EGFR ERBB2 TP53
16
Show member pathways
12.33 AKT1 CCND1 EGFR ERBB2 ESR1 PTGS2
17
Show member pathways
12.3 AKT1 BRCA1 CCND1 TP53
18 12.29 AKT1 CCND1 EGFR ERBB2 ESR1 TP53
19
Show member pathways
12.27 BRCA1 CCND1 CDKN2A ESR1 PGR
20
Show member pathways
12.21 AKT1 CCND1 EGFR ERBB2 TP53
21
Show member pathways
12.17 AKT1 CCND1 EGFR ERBB2
22 12.15 AKT1 CCND1 CDH1 EGFR PTGS2 TP53
23 12.13 AKT1 CCND1 CDKN2A TP53
24
Show member pathways
12.12 AKT1 CCND1 EGFR ERBB2
25 12.11 AKT1 CLDN7 EGFR TP53
26
Show member pathways
12.08 AKT1 EGFR ERBB2 TP53
27 12.06 CCND1 EGFR PTGS2 TP53
28 12.04 AKT1 CCND1 ESR1 TP53
29 12.03 AKT1 CCND1 CDKN2A ERBB2 TP53
30 12.02 AKT1 CCND1 MUC1 PTGS2 TP53
31 12 AKT1 CCND1 CDKN2A EGFR TP53
32
Show member pathways
11.99 AKT1 EGFR TP53
33
Show member pathways
11.99 EGFR ERBB2 ESR1 PGR
34
Show member pathways
11.95 AKT1 BRCA2 CCND1 CDKN2A EGFR ERBB2
35 11.91 AKT1 BRCA1 CCND1 EGFR
36 11.87 AKT1 CCND1 PTGS2 TP53
37 11.85 AKT1 KRT14 KRT5 TP53
38
Show member pathways
11.77 AKT1 CDKN2A TP53
39 11.76 CDH1 EGFR ERBB2
40
Show member pathways
11.75 CCND1 EGFR ESR1
41 11.74 AKT1 EGFR ERBB2
42 11.74 AKT1 BRCA1 ERBB2 TP53
43 11.73 AKT1 CCND1 EGFR ESR1
44 11.72 AKT1 EGFR ERBB2 TP53
45 11.69 AKT1 BRCA1 CDKN2A ERBB2 TP53
46 11.68 BRCA1 CCND1 ERBB2 S100A7
47 11.66 AKT1 BRCA1 CCND1
48 11.66 CCND1 CDH1 CDKN2A EGFR ERBB2 TP53
49 11.63 AKT1 CCND1 TP53
50 11.59 CCND1 CDKN2A EGFR TP53

GO Terms for Ductal Carcinoma in Situ

Cellular components related to Ductal Carcinoma in Situ according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.89 AKT1 BRCA1 BRCA2 CCND1 CDKN2A EGFR
2 protein complex GO:0043234 9.63 AKT1 BRCA1 BRCA2 ESR1 PTGS2 TP53
3 cytoplasm GO:0005737 9.55 AKT1 BRCA1 BRCA2 CCND1 CDH1 CDKN2A

Biological processes related to Ductal Carcinoma in Situ according to GeneCards Suite gene sharing:

(show all 25)
id Name GO ID Score Top Affiliating Genes
1 cell proliferation GO:0008283 9.96 AKT1 BRCA2 EGFR ERBB2 TP53
2 positive regulation of protein phosphorylation GO:0001934 9.85 AKT1 CCND1 EGFR ERBB2
3 cellular response to mechanical stimulus GO:0071260 9.79 AKT1 EGFR PTGS2
4 response to estrogen GO:0043627 9.77 BRCA1 CCND1 ESR1
5 positive regulation of smooth muscle cell proliferation GO:0048661 9.77 AKT1 EGFR PTGS2
6 positive regulation of transcription, DNA-templated GO:0045893 9.76 AKT1 BRCA1 BRCA2 CDH1 CDKN2A EGFR
7 cellular response to growth factor stimulus GO:0071363 9.75 AKT1 EGFR ERBB2
8 phosphatidylinositol-mediated signaling GO:0048015 9.73 AKT1 EGFR ERBB2 TP53
9 epidermis development GO:0008544 9.71 EGFR KRT14 KRT5 S100A7
10 cellular response to epidermal growth factor stimulus GO:0071364 9.69 AKT1 EGFR ERBB2
11 positive regulation of nitric oxide biosynthetic process GO:0045429 9.67 AKT1 EGFR PTGS2
12 response to estradiol GO:0032355 9.67 CCND1 EGFR ESR1 PTGS2
13 positive regulation of vasoconstriction GO:0045907 9.63 AKT1 EGFR PTGS2
14 hemidesmosome assembly GO:0031581 9.62 KRT14 KRT5
15 response to organic substance GO:0010033 9.62 AKT1 CCND1 CDH1 PTGS2
16 mitotic G1 DNA damage checkpoint GO:0031571 9.61 CCND1 TP53
17 positive regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycle GO:0031659 9.58 AKT1 EGFR
18 negative regulation of immature T cell proliferation in thymus GO:0033088 9.54 CDKN2A ERBB2
19 cellular response to indole-3-methanol GO:0071681 9.52 BRCA1 CDH1
20 chordate embryonic development GO:0043009 9.48 BRCA1 BRCA2
21 response to X-ray GO:0010165 9.43 BRCA2 CCND1 TP53
22 response to UV-A GO:0070141 9.13 AKT1 CCND1 EGFR
23 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 8.92 BRCA1 BRCA2 MUC1 TP53
24 positive regulation of transcription from RNA polymerase II promoter GO:0045944 10.11 AKT1 BRCA1 CDKN2A EGFR ESR1 PGR
25 cellular response to DNA damage stimulus GO:0006974 10 AKT1 BRCA1 BRCA2 CCND1 TP53

Molecular functions related to Ductal Carcinoma in Situ according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.91 AKT1 CLDN7 EGFR ERBB2 ESR1 TP53
2 protein kinase binding GO:0019901 9.73 AKT1 CCND1 CDKN2A EGFR ESR1 TP53
3 protein phosphatase binding GO:0019903 9.58 EGFR ERBB2 TP53
4 glycoprotein binding GO:0001948 9.5 CDH1 EGFR PIP
5 signal transducer, downstream of receptor, with protein tyrosine kinase activity GO:0004716 9.37 EGFR ERBB2
6 enzyme binding GO:0019899 9.23 AKT1 BRCA1 CCND1 EGFR ESR1 PGR
7 nitric-oxide synthase regulator activity GO:0030235 9.13 AKT1 EGFR ESR1
8 protein binding GO:0005515 10.13 AKT1 BRCA1 BRCA2 CCND1 CDH1 CDKN2A

Sources for Ductal Carcinoma in Situ

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....